Start Here: Tell Us the CAPA Story

• In one sentence, how would you describe your current CAPA process?
• How many active CAPAs are currently open across your organization? Options: 0–10, 11–25, 26–50, 51–100, 101–250, 250+
• What primary system do you use to manage CAPAs today? Options: Spreadsheets, Paper / shared drives, General QMS (not CAPA‑specialized), Homegrown database/tool, Dedicated CAPA management solution, Other
• When you think about how CAPAs actually get created, where do most originate from? Options: Deviations, Complaints, Internal audits, External audits/inspections, Trend analysis, Other
• Who on your team is usually the first person to own a CAPA? (role/title) Options: Quality Director, CAPA Manager / Lead, Quality Engineer, Regulatory Lead, Department Manager, Other
• Describe a recent CAPA you felt was handled well — what made it stand out?

Are We Just Applying Band‑Aids?

• How often do you suspect CAPAs address symptoms rather than true root causes? Options: Almost always, Often, Sometimes, Rarely, Never sure
• Which types of CAPA investigations most commonly circle back as repeat issues? Options: Process deviations, Supplier quality, Device complaints, Software/IT issues, Environmental controls, Other
• Give an example of a recurring issue you believe wasn’t fully resolved — what was tried, and what kept it coming back?
• How long, on average, from CAPA initiation to final effectiveness verification in your organization? Options: <30 days, 30–90 days, 91–180 days, 181–365 days, >1 year, Varies widely
• What typically derails an investigation from reaching a defensible root cause (pick all that apply)? Options: Lack of investigation methodology, Insufficient evidence collection, Stakeholder non‑engagement, Pressure to close quickly, Limited data access, Other
• When an action under a CAPA is late or incomplete, how is that usually escalated or remediated? Options: Automated reminders, Manual follow‑ups, Escalation to management, No consistent escalation, Other

If FDA Called Tomorrow: What Would Make You Nervous?

• Where do you feel most exposed during an FDA review of your CAPAs? Options: Root cause analysis quality, Effectiveness checks, Traceability to deviations/complaints, Audit trail / signatures, Timeliness of actions, Other
• Have you received any FDA 483s or audit findings related to CAPA in the last 3 years? If yes, what was cited? Options: No findings, CAPA inadequate investigation, Ineffective corrective actions, Poor documentation / traceability, Effectiveness not demonstrated, Other
• How do you currently document and prove that an effectiveness check actually validated elimination of the root cause? Options: Measurement data with trend analysis, Audit/follow‑up sampling, Process performance metrics, Qualitative confirmation only, We struggle to demonstrate this
• Describe any gaps in electronic records or Part 11 controls (e‑signatures, audit trails) that would worry you in an inspection.
• If an inspector asked to see the chain linking a complaint→investigation→corrective action→effectiveness check, how confident would you be in producing a complete, timestamped trail? Options: Completely confident, Mostly confident, Some gaps but can assemble, Not confident

Who's Holding the Reins (and Who's Running in Circles)?

• Who truly owns CAPA outcomes in your organization — is it quality, operations, or a shared responsibility? Options: Quality fully owns, Operations owns with Quality oversight, Shared RACI, No clear ownership, Other
• Which stakeholder groups are regularly involved in investigations and action implementation? Options: Quality, Manufacturing/Operations, R&D, Regulatory, Supply Chain / Suppliers, Clinical, Other
• What incentives or disincentives influence timely action completion (positive or negative)?
• How often do you have cross‑functional reviews or governance meetings focused on CAPA effectiveness? Options: Weekly, Biweekly, Monthly, Quarterly, Ad hoc / rarely
• Where do handoffs most often break down—investigation, implementation, verification, or management review? Options: Investigation, Implementation, Effectiveness verification, Management review, Handoffs generally fine
• If you could change one role or process to improve CAPA execution, what would it be and why?

Show Me a CAPA That Proved the Process Works

• Can you identify one or two CAPAs in the past 12 months that demonstrably stopped recurrence? Tell the story.
• Which investigation methodologies did those successful CAPAs use? Options: 5‑Why, Fishbone / Ishikawa, Fault Tree Analysis, Pareto / trend analysis, Design of Experiments (DOE), Other
• What tangible metrics showed success for those CAPAs (e.g., defect rate drop, fewer complaints, cost savings)? Options: Defect rate reduction, Fewer customer complaints, Reduced scrap/rework, Fewer repeat deviations, Time to close decreased, Other
• How was evidence captured and retained so the CAPA remained defensible months later? Options: Structured investigation report, Linked artifacts (photos, test reports), Timestamped electronic trail, Separate validation documentation, We did not retain adequate evidence
• What about those cases felt repeatable — could that approach be scaled, and if not, why?

What Would a Good Day Feel Like?

• If your CAPA program reduced recurrence by 50% in a year, what upstream changes would have to happen?
• Which success metrics matter most to your leadership in CAPA performance? Options: Recurrence rate, Average time to close, Percent of CAPAs with validated effectiveness, Audit findings related to CAPA, Management review KPIs, Other
• What acceptance criteria would you use to sign off on a CAPA program improvement project? Options: Quantified reduction in recurrence, Regulatory audit readiness, Faster investigation times, Automated traceability between records, All actions completed on time, Other
• How would daily workflows need to change so investigators and implementers actually follow structured methodologies?
• What reporting or dashboard views would make you feel in control every week? Options: Risk‑ranked open CAPAs, Overdue action list with owners, Trend of root causes, Effectiveness verification status, Management review snapshots, Other
• If you had one unobstructed week with your team, what one CAPA outcome would you push to achieve?

What Would It Take to Change?

• What is the single biggest barrier that will stop your team from adopting a more rigorous CAPA approach? Options: Budget, Lack of executive buy‑in, Change fatigue, Integration/IT constraints, Validation workload, Other
• How will validation and compliance obligations (IQ/OQ/PQ, Part 11, SOP updates) influence timeline and budget decisions? Options: Major impact — must budget separately, Moderate — manageable in project, Minor impact, Unsure
• Which decision‑makers need to be persuaded before you can move forward (roles/titles)?
• What pilot or proof‑of‑value would convince leadership to invest in a CAPA platform? Options: Pilot on high‑risk product line, Demonstration with two real CAPAs, ROI model showing cost savings, Audit readiness simulation, Other
• Realistically, what budget range and timeline would you be comfortable committing to for a meaningful CAPA transformation? Options: <$50k / <3 months, $50k–$150k / 3–6 months, $150k–$500k / 6–12 months, >$500k / 12+ months, Undecided
• What would success look like for a first 90‑day engagement — name three measurable outcomes you’d expect?

• Solution Experience Kickoff & Case Selection
• Case Walkthrough — Diagnosis (Case A)
• Case Walkthrough — Proof (Case A) — Structured Investigation & Traceability
• Second Case (if selected) + Consolidation, Acceptance Criteria & Next Steps

• Both: Schedule pilot kickoff and assign validation and governance owners.
• Seller: Prepare a storyboard showing exactly which platform capabilities will be used to demonstrate the future state for Case A.
• Recap Agreed Problem & Goal
• Prove, with customer data, that the platform achieves the agreed future state for Case A.
• Tie each demonstrated capability back to a specific problem or consequence identified in Diagnosis.
• Obtain explicit validation from the customer at defined checkpoints.
• Identify any configuration gaps or compliance questions requiring follow‑up (e.g., Part 11 nuances).
• Seller: Deliver the session recording, configuration notes, and the proposed workflow template for Case A.
• Customer: Confirm whether the demonstrated workflow and fields meet their investigation rigor and compliance needs or note adjustments.
• Seller Compliance SME: Prepare a short mapping of Part 11/e-signature controls used in the demo for customer review.
• Optional Quick Diagnosis Recap (Case B)
• Either validate Case B with the same rigor or extract repeatable configuration patterns from Case A.
• Finalize a clear pilot/POC scope with objective acceptance criteria tied to customer success signals.
• Secure commitment on owners, timeline, and the decision gate for pilot success.
• List any compliance or technical items requiring immediate resolution prior to pilot start.
• Seller: Draft and share the pilot/POC scope document, including acceptance criteria and timeline.
• Customer: Approve pilot scope and provide required system access, sanitized data extracts, and stakeholder availability.
• Introductions & Objectives
• Confirm 1–2 real CAPA cases and assign owners for each.
• Ensure customer commits to delivering required artifacts and metrics before the walkthrough.
• Agree the exact success signals and validation checkpoints for the experience.
• Align on rules of engagement so the session stays diagnosis→proof→validation.
• Customer: Deliver full case artifacts (investigation notes, timelines, evidence, corrective actions, effectiveness checks) for selected cases.
• Seller: Produce a meeting plan and confirm access needs (screenshots, system access, sanitized data) for each walkthrough.
• Both: Schedule detailed walkthrough meetings and assign attendees.
• Customer Summary (Current State, 1 sentence)
• Produce a crystal‑clear one‑sentence current state for Case A.
• Surface and quantify the concrete consequences (cost, risk, recurrence) so urgency is explicit.
• Define a one‑sentence future state outcome that constitutes 'better' for this case.
• List specific data or gaps to be provided/resolved before the Proof meeting.
• Customer: Provide any missing metrics, logs, or stakeholder clarifications identified during mapping.
• Seller: Create a concise problem statement and a mapped list of gaps that will be addressed in the Proof session.
• Solution Experience Rules
• Guided Reconstruction of the Investigation
• Process & Evidence Mapping
• Proof Highlights (Case B or Consolidated Patterns)
• Case Selection Criteria
• Quantify Consequences
• Traceability & Action Mapping
• Define Pilot/POC Scope & Acceptance Criteria
• Artifacts & Data Needed (Pre‑work)
• Root Cause Gaps
• Governance, Timeline & Decision Gate
• Effectiveness Check & Reporting
• Agree Future State Outcome (1 sentence)
• Define Success Signals & Validation Checks
• Validation Q&A (Forced Confirmation)
• Confirm Next Steps & Assignments
• Logistics & Owners

• Configure CAPA Workflow and Approval Gates
• Deploy Event Capture and Intake Forms
• Implement Root Cause Analysis Tools (5-Why, Fishbone, FTA)
• Configure Corrective and Preventive Action Tracking
• Link CAPAs to Deviations, Complaints, and Audits
• Enable Risk-Based Prioritization and Scoring
• Set Up Automated Escalations and Notifications
• Activate Electronic Signatures and Full Audit Trail
• Integrate CAPA Platform with Existing QMS/ERP
• Build Management Review and CAPA KPI Dashboards
• Migrate Existing CAPA Records and Historical Data
• Deliver End-User Training and CAPA SOP Templates
• Provide Validation Package (IQ/OQ/PQ) and Evidence

Configure CAPA Workflow and Approval Gates

• Do you currently have a formal CAPA workflow with defined stages and approval gates? Options: Yes, No
• How many approval gates or formal review points do you require in a typical CAPA lifecycle? Options: None, 1-2, 3-4, 5+
• Which roles must be able to review/approve CAPA stages? Options: Quality Director, CAPA Manager, QA Reviewer, Manufacturing Lead, Regulatory, R&D, Other
• Do you require conditional routing (e.g., routing based on risk score, site, or product line)? Options: Yes, No
• What SLAs should be enforced at each gate (time-to-approve or escalate)? Options: <48 hours, 2-7 days, >7 days, Custom
• Are there exceptions or manual override rules we should model in the workflow? (If yes, describe)

Deploy Event Capture and Intake Forms

• What event sources must be supported for intake (select all that apply)? Options: Deviation, Complaint, Audit Finding, Near-Miss, Customer Feedback, Supplier Nonconformance, Other
• Do you have existing intake forms/templates to replicate or should we design new ones? Options: Replicate existing, Design new, Hybrid
• What required fields or validations must be enforced on intake (e.g., product, lot, severity, attachments)?
• Do intake forms need to capture electronic attachments (e.g., photos, test reports) and what max size or retention policy applies? Options: Yes, No
• Should event capture be available via mobile/field entry or only internal desktop users? Options: Desktop only, Mobile + Desktop, API-only (system-to-system)
• Are there specific user groups who should have simplified or restricted intake forms (e.g., shop floor vs. QA)? Options: Yes, No

Implement Root Cause Analysis Tools (5-Why, Fishbone, FTA)

• Which RCA methodologies should be enabled out-of-the-box? Options: 5-Why, Fishbone (Ishikawa), Fault Tree Analysis (FTA), Pareto/Trend Analysis, Other
• Do you require guided/templates for RCA steps (mandatory fields and evidence) or free-form RCA? Options: Guided templates, Free-form, Both (configurable per CAPA)
• Should RCA outputs be linked to evidence (test data, photos, logs) and retained as part of the CAPA record? Options: Yes, No
• Do you need role-based RCA collaboration (e.g., assign SMEs, reviewers, contributors)? Options: Yes, No
• Are there organization-specific root cause taxonomies or codes to import? Options: Yes, No
• Do you want automatic traceability from each identified root cause to corrective actions and verification steps? Options: Yes, No

Configure Corrective and Preventive Action Tracking

• Should actions be tracked as individual tasks with owners and due dates or as batch activities? Options: Individual tasks, Batch activities, Both
• Do you require mandatory fields for actions (owner, due date, priority, evidence of completion)? Options: Yes, No
• Should the system enforce re-opening or follow-up actions if effectiveness checks fail? Options: Yes, No
• What types of action status and lifecycle states are required (e.g., planned, in-progress, implemented, verified)?
• Do corrective/preventive actions need to trigger change control, training, or CAPEX requests automatically? Options: Yes, No
• Are recurring or preventive actions required (periodic tasks) and how should recurrence be configured? Options: None, Manual recurrence, Configurable scheduled recurrence

Link CAPAs to Deviations, Complaints, and Audits

• Which source systems hold deviations/complaints/audit records that must be linked? Options: Excel/Spreadsheets, Legacy eQMS, ERP, LIMS, MES, ServiceNow/ITSM, Other
• Do you want one-way links (CAPA references event) or bi-directional linking (event references CAPA and status)? Options: One-way, Bi-directional
• Should linking be automatic (rules-based) or manual selection by users? Options: Automatic rules-based, Manual only, Hybrid
• Will linking require cross-site or multi-plant visibility and access controls? Options: Yes, No
• Are there bulk-linking or bulk-unlinking needs for historical data migration? Options: Yes, No
• Describe any regulatory traceability expectations between CAPAs and audits/complaints (e.g., citation numbers, audit report IDs).

Enable Risk-Based Prioritization and Scoring

• Do you currently use a risk matrix or scoring model for CAPA prioritization? Options: Yes, No
• Which risk criteria should be included (select all that apply)? Options: Patient safety/health impact, Regulatory impact, Production impact, Financial impact, Likelihood/Probability, Other
• What scoring scale do you prefer? Options: Low/Medium/High, 1-5, 1-10, Custom
• Should the platform auto-calculate priority based on inputs or allow manual override? Options: Auto-calculate only, Manual override only, Auto with manual override
• Do priority thresholds need to trigger different workflows or escalation paths? Options: Yes, No
• Are any regulatory or corporate policies required to be encoded into the scoring logic (e.g., always escalate safety-related events)? Options: Yes, No

Set Up Automated Escalations and Notifications

• Which notification channels should be enabled? Options: Email, SMS, Microsoft Teams, Slack, In-app notifications, Webhook/API
• What conditions should trigger escalations (e.g., overdue action, high-risk CAPA, failed verification)?
• How many escalation tiers are needed (e.g., owner -> manager -> director)? Options: None, 1, 2, 3+
• Do escalation notifications require audit logging and escalation history for compliance? Options: Yes, No
• Should recipients be dynamic (based on role, site, product) or fixed distribution lists? Options: Dynamic by role/site, Fixed lists, Both
• Are SLA timers or reminder frequencies required to be configurable per CAPA type or priority? Options: Yes, No

Activate Electronic Signatures and Full Audit Trail

• Do you require 21 CFR Part 11 compliant electronic signatures? Options: Yes, No, Unsure - need guidance
• Which actions require e-signature (select all that apply)? Options: CAPA approval, Effectiveness verification, Action closure, SOP acknowledgement, Validation sign-off, Other
• How many distinct signer roles or identity levels must be configured (e.g., preparer, reviewer, approver)? Options: 1-2, 3-4, 5+
• Do you need audit trail exports or reports for inspections (PDF/CSV) and retention policy settings? Options: Yes, No
• Is integration with your identity provider (SSO/SAML) required for e-signature authentication? Options: Yes, No
• Are there specific timestamp or timezone requirements for signature records? Options: UTC, Local site timezone, Both (store UTC + local)

Integrate CAPA Platform with Existing QMS/ERP

• Which systems must be integrated (select all that apply)? Options: ERP (SAP/Oracle), LIMS, MES, Existing eQMS, HR/Training LMS, ServiceNow/ITSM, Other
• What integration pattern do you require? Options: Real-time API, Scheduled batch sync, File drop (CSV/XML), Manual import only
• Do target systems expose APIs or will custom connectors be required? Options: APIs available, No APIs - custom connector required, Unsure - need to confirm
• Should the CAPA platform be the system-of-record for CAPAs or should records be synchronized bi-directionally? Options: CAPA platform as SoR, Bi-directional sync, One-way to CAPA platform
• Are there data mapping or field translation rules to capture (please list critical fields if known)?
• Estimate daily/weekly transaction volume for integrations (number of events or API calls). Options: <100, 100-1,000, 1,000-10,000, 10,000+

Build Management Review and CAPA KPI Dashboards

• Which KPIs must be included on management dashboards (select all that apply)? Options: Open CAPAs, Overdue CAPAs, MTTR (time to close), Recurrence rate, Effectiveness check pass rate, CAPAs by site/product, Other
• Do dashboards need role-based visibility (site-level vs corporate) and data filters? Options: Yes, No
• Do you require scheduled management reports (PDF/email) and cadence (weekly, monthly, quarterly)? Options: Yes, No
• Should dashboards include drill-down from KPI to CAPA detail and attached evidence? Options: Yes, No
• Are there specific visualizations preferred (tables, trend lines, heat maps)? Options: Tables, Trend lines, Heat maps, Bar/column charts, Custom
• Do you require KPI thresholds to automatically trigger alerts or escalation workflows? Options: Yes, No

• Non-Disclosure Agreement (NDA)
• Master Services Agreement (MSA)
• Statement of Work (SOW)
• Pricing & Payment Terms
• Service Level Agreement (SLA)
• Software Licensing Agreement
• Data Processing Agreement (DPA)
• Validation & Compliance Addendum
• Acceptance Criteria & Success Metrics
• Implementation Timeline & Milestones
• Governance, Roles & Escalation Plan
• Change Order Agreement
• Training, Validation Scripts & Handover
• Warranty, Support & Maintenance Agreement
• Purchase Order / Procurement Authorization
• Third-Party Integration Responsibility Matrix

• Success Metrics Validation - Monthly Review
• Effectiveness Check Deep Dive (Sample-Based)
• Audit Readiness & Evidence Package Review
• Enhancement Backlog & Issue Triage
• Executive Outcomes & Governance Review (Quarterly)

• Create prioritized backlog tickets with acceptance criteria, compliance impacts, and validation needs.
• Update the effectiveness-check template and SOP guidance based on recurring gaps found.
• Regulatory Risk & Scope Summary
• Confirm completeness and defensibility of evidence packages for inspection.
• Ensure Part 11 and validation controls are demonstrable and documented.
• Assign owners and timelines for any outstanding items required to reach inspection readiness.
• Compile and finalize the inspector evidence binder (electronic and paper) and circulate to owners.
• Remediate any identified Part 11 or validation gaps with assigned IT/validation owners.
• Schedule a full mock audit within agreed timeline and confirm participant availability.
• Document inspection day runbook and communication plan.
• Review New Issues & Tickets
• Convert operational findings into a prioritized, risk-ranked backlog with clear owners.
• Agree on timing and resources for remediation and product enhancements.
• Identify immediate quick wins to reduce near-term recurrence risk.
• Opening and Objectives
• Assign development/validation owners and target release windows for high-priority items.
• Implement identified quick wins and confirm completion in the next success review.
• Notify stakeholders of roadmap changes and expected user impacts.
• Executive Summary of Outcomes
• Obtain executive alignment on program success metrics and next-quarter priorities.
• Secure resources and approvals for high-impact remediation or enhancements.
• Reinforce governance cadence and responsibility for ongoing audit readiness.
• Approve requested budget/resources for critical remediation projects.
• Assign executive sponsor(s) for escalated compliance risks and roadmap initiatives.
• Publish executive summary and updated governance RACI to stakeholders.
• Schedule the next quarterly governance review and pre-read distribution timeline.
• Confirm KPIs demonstrate measurable improvement (reduced recurrence and timely effectiveness checks).
• Validate that sampled CAPAs include defensible evidence of root cause elimination.
• Identify and assign remediation for CAPAs or processes that fail to meet acceptance criteria.
• Align next review date and owners for ongoing monitoring.
• Owner(s) to remediate flagged CAPAs with inadequate evidence and provide updated packets by agreed date.
• Update KPI dashboard definitions and thresholds if metric clarity issues were found.
• Schedule follow-up sample validation meeting for reopened CAPAs.
• Document decisions and circulate meeting minutes and assigned owners within 48 hours.
• Purpose, Scope & Sample Selection
• Verify that effectiveness checks provide credible evidence that the root cause was eliminated.
• Decide on closure or rework for each sampled CAPA based on documented evidence.
• Capture process improvements for future effectiveness-check design and templates.
• Re-open CAPAs where evidence is insufficient and assign remediation owners with deadlines.
• Define additional monitoring or sampling plans for borderline cases.
• KPI/Dashboard Review
• Risk & Impact Assessment
• Evidence Package Walkthrough
• Sample 1 Evidence Review
• Regulatory & Risk Highlights
• Sample 2 Evidence Review
• Sample Case Validation
• Operational & Financial Impact
• Prioritization & Resource Assignment
• Part 11 & Validation Controls Check
• Quick Wins & Process Fixes
• Sample 3 Evidence Review (if applicable)
• Open Observations & Aging Review
• Trend & Root-Cause Recurrence Analysis
• Governance Decisions & Resourcing
• Strategic Next Steps & Commitments
• Effectiveness Check Timeliness & Quality
• Mock Inspector Q&A & Evidence Requests
• Methodology & Acceptance Criteria Check
• Roadmap & Release Coordination